TY  - GEN
AU  - Gross-Goupil,M
AU  - Kwon,T G
AU  - Eto,M
AU  - Ye,D
AU  - Miyake,H
AU  - Seo,S I
AU  - Byun,S-S
AU  - Lee,J L
AU  - Master,V
AU  - Jin,J
AU  - DeBenedetto,R
AU  - Linke,R
AU  - Casey,M
AU  - Rosbrook,B
AU  - Lechuga,M
AU  - Valota,O
AU  - Grande,E
AU  - Quinn,D I
TI  - Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
SN  - 1569-8041
PY  - 2019///1125
KW  - Administration, Oral
KW  - Aged
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Axitinib
KW  - Carcinoma, Renal Cell
KW  - mortality
KW  - Chemotherapy, Adjuvant
KW  - methods
KW  - Disease-Free Survival
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Intention to Treat Analysis
KW  - Kidney Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Nephrectomy
KW  - Placebos
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdy454
ER  -